# Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer

> **NCT03450330** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dizal Pharmaceuticals** · enrollment: 10 (actual)

## Conditions studied

- Nonsmall Cell Lung Cancer

## Interventions

- **DRUG:** AZD4205

## Key facts

- **NCT ID:** NCT03450330
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-16
- **Primary completion:** 2019-09-03
- **Final completion:** 2020-01-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03450330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03450330, "Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03450330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*